Stock Analiz

Curis Inc. CRIS

Biotechnology: Biological Products (No Diagnostic Substances) · data as of November 13, 2026

$0.45Market cap $3M
Open the interactive analysis →

Curis Inc. (CRIS) is a healthcare company listed in the US with a market value of about $3M. In fiscal year 2025 it had revenue of $9M and net income of -$8M, a net margin of -80.3%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of -3% a year, a 5-year average ROIC of -217%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.

About Curis

Curis is listed in the US and classified in biotechnology: biological products (no diagnostic substances). Revenue went from $10M in 2014 to $9M in 2025, a decline of about 0.4% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 182% over three years (dilution for shareholders). It spends 299% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth2/5
Track record0/5
Financial health1/5
Shareholder returns0/5

Checks passed

  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.3
P/B1.2
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−83%

Growth and quality

Revenue growth (1 yr)-13.4%
Revenue growth (5 yrs, per year)-2.7%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-387.1%
ROIC (5-yr avg.)-216.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$9M$11M$10M$10M$11M$11M$10M$10M$10M$8M
Net income-$8M-$43M-$47M-$57M-$45M-$30M-$32M-$33M-$53M-$60M
Free cash flow——-$38M-$55M-$38M-$26M-$26M-$30M-$49M-$36M
EPS (diluted)$-1.16$-13.76$-17.92$-24.28$20.00$-24.40$-38.80$-39.20$-71.60$-90.00
Net margin-80.3%-397.8%-473.0%-557.7%-426.7%-276.0%-321.3%-312.4%-538.7%-802.6%
ROIC-63.7%-779.9%-123.3%-83.0%-34.7%-14.2%—-74.8%-60.0%-93.0%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 3 analysts is $30.33, 6716% above the current price; targets range from $6.00 to $65.00; the consensus rating is “Strong buy”; expected EPS is $-8.05 for the fiscal year ending December 31, 2026.

Frequently asked questions

Is Curis stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Curis pay a dividend?

Not currently.

Is Curis a good stock to buy?

We do not give buy or sell advice. Curis scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.